Notice of Application to Register Two Trade Name Products (Notice No. MPI ACVM 121)
Notice is given under section 14(1) of the Agricultural Compounds and Veterinary Medicines Act 1997 (“Act”), of the following applications to register two trade name products under section 9(1) of the Act:
Trade Name: Portela 2.5mg; Portela 6.4mg
Reference: A012277; A012278
Active Ingredients and Concentrations:
Relfovetmab 2.5mg/mL; 6.4mg/mL
Formulation Type: Aqueous solution
Application method/administration route: For subcutaneous use. The recommended dose rate is 0.5 – 1.25mg/kg bodyweight, once every three months.
General Use Claim:
For the alleviation of pain associated with osteoarthritis in cats.
Other Information:
Relfovetmab is a long-acting felinised monoclonal antibody targeting feline nerve growth factor (NGF) expressed through recombinant techniques in Chinese hamster ovary (CHO) cells.
Any person may make a written submission to the Director-General concerning this application.
Under sections 16 and 17 of the Act, a written submission:
Each submission must state the trade name product(s) to which it relates. Under section 18 of the Act, a copy of every submission will be forwarded to the applicant.
The following address is:
ACVM Team, Ministry for Primary Industries, Charles Fergusson Building, 38–42 Bowen Street, Pipitea, Wellington 6011. Postal Address: PO Box 2526, Wellington 6140. Email: acvm.consultation@mpi.govt.nz.
MPI encourages submission by email.
The applicant’s address for service is:
Zoetis New Zealand Limited, Level 4, 8 Mahuhu Crescent, Auckland Central, Auckland 1010. Postal Address: Zoetis New Zealand Limited, PO Box 2094, Shortland Street, Auckland 1140.
Dated at Wellington this 1st day of May 2026.
SHALEEN NARAYAN, Manager Approvals, Ministry for Primary Industries (acting under delegated authority).